Argenx Announces Results of Phase 3 Clinical Trial

Cheers to H+C client argenx for announcing results of their first Phase 3 clinical trial. 👏 Positive results demonstrated significant improvements in the daily living activities of certain patients living with rare muscle disease #myastheniagravis Shot 2020 05 29 At 4.02.59 Pm


Join The Conversation

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow us on instagram